HealthMore in Health→
Biogen and Denali Pull Back a Parkinson’s Program After a Mid-Stage Failure
Biogen and Denali Therapeutics are dropping their LRRK2 inhibitor program in certain patients with non-genetic Parkinson’s disease after the drug failed a Phase 2b study in early Parkinson’s.
Key Takeaways
- Biogen and Denali’s LRRK2 inhibitor failed a Phase 2b study in early Parkinson’s disease.
- The companies are dropping the program in certain patients with non-genetic Parkinson’s.
DE
DT Editorial Team··via endpoints.news